bull

baseposting, gtm helper, ai infra biz

[bull @ChainlinkBull]

trade culture over attention

attention flows where the culture goes

[bull @ChainlinkBull]

@0xHaley_ Didn’t check. I just like the tech.

[bull @ChainlinkBull]

$EDEL looks good here

[bull @ChainlinkBull]

In SF for the weekend

[Richard E. Ptardio @RichardPtardio]

Since Mrs Ptardio left me, Arsenal have won the Premier League and hyperliquid:native has reached a new all-time high.

I do not wish to imply the woman was suppressing global markets.

But one must, at my age, respect the data.

[bull @ChainlinkBull]

@boborado @edshrag we can get you B300s deployed faster than then. DM.

[bull @ChainlinkBull]

@ramahluwalia @CommodMkt interesting. would love to chat.

[bull @ChainlinkBull]

$LINK to triple digits

[🟩 Ibrahim @Ikh011]

LayerZero has lost $4B in TVL after 5 major protocols migrated to Chainlink's CCIP

You get hacked once and its over

[bull @ChainlinkBull]

@lindaxie @1startupcentral is a hard tech incubator that also has a data center. worth a look.

[bull @ChainlinkBull]

mission-critical infrastructure wins on long-term horizons

$link

[Kraken @krakenfx]

Kraken is deprecating its existing cross-chain provider and migrating to @Chainlink CCIP as its exclusive cross-chain infra to secure Kraken Wrapped Bitcoin (kBTC) & all future Kraken Wrapped Assets.

Kraken chose Chainlink CCIP because it offers enterprise-grade infrastructure with strict security & risk management requirements, including:

• ISO 27001 and SOC 2 Type 2 certifications
• Secure by default architecture
• 16 independent nodes
• Native rate limits, and more.

Together, Chainlink and Kraken can help accelerate the global adoption of crypto by unlocking utility and distribution for all Kraken Wrapped Assets across DeFi.

For kBTC customers, no action is required. More details on the migration process to follow on official Kraken channels.

[bull @ChainlinkBull]

@horizon_compute @andr3w lol

[bull @ChainlinkBull]

@andr3w Chad

[Adam Knuckey 🏔 @adam_knuckey]

https://t.co/gTJsm7GxsN

[bull @ChainlinkBull]

@JoshuaKushner Highkey know people doing this. But in Indonesia not US.

[bull @ChainlinkBull]

@investmattallen Building for this bottleneck currently. Thank you for affirming my thesis.

[bull @ChainlinkBull]

@DrBillCosby @antiscarcity @chamath @grok chad.

[bull @ChainlinkBull]

@antiscarcity @chamath dc electricians are making >$200k a year. huge boon for all sorts of skilled labor folks.

[bull @ChainlinkBull]

@chamath if you are interested in data centers we have a niche we are carving out. found points of regulatory arbitrage. DM is open.

[STU ⬡ @Voyager4IR]

The $LINK token is crucial and very much needed. Mass-scale production from major players like Swift is just around the corner.

[Bankless @Bankless]

Bio Protocol designed a novel ADHD drug candidate in 24 hours using AI. First lab test: $500. Full validation: ~$1,500. Pharma spends millions and years to reach the same point.

That changes what DeSci can do. Drug development has always been gated by capital, not science.

Research gets funded when it aligns with commercial priorities. Plenty of valuable questions never get asked because no one with the budget chose to ask them. DeSci has been working on that gap for years, but the ambition stayed kneecapped by the cost of discovery itself.

AI changes the math. With costs this low, a DAO treasury can fund a drug candidate all the way validation with real lab data. Entire categories of research pharma was NEVER going to touch are now within reach.

Yet, three problems persister that AI + community funding can't clear alone:

- Data inaccessibility: the training data AI needs to validate further sits locked inside pharma companies that treat it as a competitive weapon (Bio and Molecule are building to solve this via Science Beach and other initiatives)

- Wet labs: even a well-characterized candidate needs physical validation on biological material. No amount of AI removes this step

- Clinical trials: testing on humans still runs on the old capital structure — tens of millions to hundreds of millions. Nothing in the DeSci stack reaches that far yet

DeSci gets candidates to the START of that path with something real in hand: a characterized compound with published binding data and a permanent record. That's a different conversation with pharma than a hypothesis and a pitch.

There's a cultural current underneath all of this. People using AI to fight their own cancer, treat their pets, research conditions pharma deprioritized. A growing cohort motivated by personal stakes, not commercial ones. DeSci pairs cleanly with this trend, giving hope that personal motivation, not profit, can soon play a larger role in discovery.

[bull @ChainlinkBull]

@andymill232 @NWischoff DM